Evidence map›Paper›PMID 17878149›Full record

Trial reportThe New England journal of medicine2007

Zoledronic acid and clinical fractures and mortality after hip fracture.

Kenneth W Lyles, Cathleen S Colón-Emeric, Jay S Magaziner, Jonathan D Adachi, Carl F Pieper, Carlos Mautalen, Lars Hyldstrup, Chris Recknor, Lars Nordsletten, Kathy A Moore and 10 more

2 registry-linked trialsOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The New England journal of medicine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 711 papers, 20 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
711citing papers in PubMed, 20 pooled it
114.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00046254 phase3completednot on this map

Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture

TypeinterventionalSponsorNovartis PharmaceuticalsRan2002 to 2007Enrolled2,127ConditionsOsteoporosis, Hip FractureArmsZoledronic Acid
NCT04229368 naunknown statusnot on this mapstarted 2019, after this paper: background citation

Effect of Vitamin D Status and Repletion on Postoperative Total Joint Arthroplasty Complications

TypeinterventionalSponsorBrigham and Women's HospitalRan2019 to 2024Enrolled900ConditionsHip Arthropathy, Knee Arthropathy, Vitamin D DeficiencyArmsVitamin D3
3 · Its place in the literature

Who cites it

711 citing papers in PubMed, 20 syntheses or guidelines pooled it, 1,983 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Romosozumab for the treatment of osteoporosis - a systematic review.Journal of endocrinological investigation · 2025
    Pooled it
  5. Pooled it
  6. Guideline
  7. Pooled it
  8. Pooled it
  9. Guideline
  10. Association between bisphosphonate use and stroke risk: a meta-analysis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2023
    Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Comparative risk of acute myocardial infarction for anti-osteoporosis drugs in primary care: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2022
    Pooled it
  15. Pooled it
  16. Guideline
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Pooled it

651 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 8 institutions in 6 countries.

Kenneth W LylesDuke University Medical Center, Durham, NC, USA.
Cathleen S Colón-Emeric
Jay S Magaziner
Jonathan D Adachi
Carl F Pieper
Carlos Mautalen
Lars Hyldstrup
Chris Recknor
Lars Nordsletten
Kathy A Moore
Catherine Lavecchia
Jie Zhang
Peter Mesenbrink
Patricia K Hodgson
Ken Abrams
John J Orloff
Zebulun Horowitz
Erik Fink Eriksen
Steven Boonen
HORIZON Recurrent Fracture Trial
Duke Medical Center · USBone Health and Osteoporosis Foundation · USHvidovre Hospital · DKKU Leuven · BEMcMaster University · CANovartis (Switzerland) · CHOslo University Hospital · NOUniversity of Maryland, Baltimore · US

Funding

Evidence-Based Medicine in the Skilled Nursing FacilityK23AG024787 · NIA · DUKE UNIVERSITY · PI COLON-EMERIC, CATHLEEN S · 2004 to 2008
$815k
Medical Research Council G0400491Medical Research Council MC_UP_A620_1014Medical Research Council U1475000001NIA NIH HHS K23 AG024787
6 · The paper itself

Abstract

backgroundMortality is increased after a hip fracture, and strategies that improve outcomes are needed.

methodsIn this randomized, double-blind, placebo-controlled trial, 1065 patients were assigned to receive yearly intravenous zoledronic acid (at a dose of 5 mg), and 1062 patients were assigned to receive placebo. The infusions were first administered within 90 days after surgical repair of a hip fracture. All patients (mean age, 74.5 years) received supplemental vitamin D and calcium. The median follow-up was 1.9 years. The primary end point was a new clinical fracture.

resultsThe rates of any new clinical fracture were 8.6% in the zoledronic acid group and 13.9% in the placebo group, a 35% risk reduction with zoledronic acid (P=0.001); the respective rates of a new clinical vertebral fracture were 1.7% and 3.8% (P=0.02), and the respective rates of new nonvertebral fractures were 7.6% and 10.7% (P=0.03). In the safety analysis, 101 of 1054 patients in the zoledronic acid group (9.6%) and 141 of 1057 patients in the placebo group (13.3%) died, a reduction of 28% in deaths from any cause in the zoledronic acid group (P=0.01). The most frequent adverse events in patients receiving zoledronic acid were pyrexia, myalgia, and bone and musculoskeletal pain. No cases of osteonecrosis of the jaw were reported, and no adverse effects on the healing of fractures were noted. The rates of renal and cardiovascular adverse events, including atrial fibrillation and stroke, were similar in the two groups.

conclusionsAn annual infusion of zoledronic acid within 90 days after repair of a low-trauma hip fracture was associated with a reduction in the rate of new clinical fractures and with improved survival. (ClinicalTrials.gov number, NCT00046254 [ClinicalTrials.gov].).

Indexed as

AgedAged, 80 and overBone DensityBone Density Conservation AgentsCalciumDiphosphonatesDouble-Blind MethodDrug Administration ScheduleDrug Therapy, CombinationFemaleFractures, BoneHip FracturesHumansImidazolesInfusions, IntravenousMaleBone Density Conservation AgentsCalciumDiphosphonatesImidazolesVitamin DZoledronic Acid

Identifiers

PMID17878149
PMCPMC2324066
OpenAlexW2163830908

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.